Company description

We are a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The physics-based nanotherapeutics we create are potentially universally applicable across patient populations, rather than targeted to impact a specific biological pathway in a particular patient. The objective of this physics-based approach is to allow our nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. We have three platforms that each seek to bring the benefits of nanotechnology to human medical problems: • Nanoradioenhancer platform: Designed to increase the tumor-killing effect of radiotherapy without increasing the dose in surrounding healthy tissues; • Nanoprimer platform: Designed to unleash the potential of innovative systemic therapeutic classes by enabling effective extrahepatic delivery; • Neurological disease platform: Designed to overcome the symptoms of debilitating neurological conditions by re-wiring the brain. Our most advanced platform has produced lead product candidate JNJ-1900 (NBTXR3) 2. Whereas most oncology drug development is focused on highly segmented patient populations with late-stage or metastatic cancer, we designed JNJ-1900 (NBTXR3) to address needs rather than targets across lines of therapy.

Read the full filing description · filed 31 Mar 2026

At a glance

Sector

Healthcare

Industry